Amersham expands Myoview to breast screening:
This article was originally published in Clinica
Executive Summary
Amersham Health has gained the go-ahead in Europe to expand the indication of its radiopharmaceutical imaging agent to use in breast cancer screening. Myoview, the company's second-largest selling product, is already well established in cardiology, where it is used to diagnose heart disease by visualising blood flow to the heart muscle, said the firm, a business of Amersham in the UK.